Recombinant human thrombopoietin safety and efficacy in pediatric allogeneic hematopoietic stem cell transplantation: A cohort study

Table 2 Neutrophil and platelet implantation of hematologic diseases in patients in different age groups

Variables	Total (n = 79)	0- to 9-year-old group (n = 36)	10- to 17-year-old group (n = 43)	P value
Time to neutrophil engraftment, day, median (range)	12 (10-32)	12 (10-20)	12 (10-32)	0.082
Time to platelet engraftment, day, median (range)	16 (11-41)	14 (11-24)	16 (11-41)	0.017
Platelet transfusions, U, median (range)	14 (4-71)	13 (5-40)	15 (4-71)	0.057
Time to platelet recovery, day, median (range)
≥ 20 × 109/L	9 (2-23)	10 (2-20)	9 (4-23)	0.942
≥ 50 × 109/L	11 (2-34)	11 (2-20)	12 (5-34)	0.351
≥ 100 × 109/L	16 (3-88)	16 (3-88)	18 (5-76)	0.037
DPE, n (%)	2 (4.0)	0	5 (11.6)	0.059
SFPR, n (%)	0	0	0

DPE: Delayed platelet engraftment; SFPR: Secondary failure of platelet recovery.